SOTROVIMAB

BRAND NAME	XEVUDY
DRUG CLASS	Immunoglobulin (IgG1) monoclonal antibody (human), antiviral (SARS-CoV-2)
AVAILABILITY	Vial contains 500 mg/8 mL of sotrovimab. Also contains histidine, histidine hydrochloride, sucrose, methionine, polysorbate-80.[1] The solution is clear and colourless to yellow or brown.[1] The vial has an overfill of 0.6 mL to allow a deliverable volume of 8 mL.[2]
WARNINGS	The occupational hazard of intermittent low dose exposure to sotrovimab is not known. Wear a mask and gloves when preparing the infusion solution to minimise exposure. Hypersensitivity reactions including anaphylaxis may occur. Resuscitation facilities must be readily available. Monitoring is required for one hour after the infusion.[1]
PREPARATION	Dilute before use.[1] Allow 15 minutes for the vial (leave in the box) to reach room temperature. Gently swirl the vial several times. **Do not shake.**[1] Remove and discard 8 mL from a 50 mL or 100 mL bag of sodium chloride 0.9% or glucose 5%.[1] If local protocols allow, this step may be omitted.[2] Add 8 mL of sotrovimab to the bag, gently rock the bag 3 to 5 times. Do not invert or shake the bag. Do not allow air bubbles to form.[1]
STABILITY	Vial: store at 2 to 8 °C. Protect from light. Do not freeze.[1] Infusion solution: stable for 6 hours below 25 °C or 24 hours at 2 to 8 °C.[1]
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Not recommended
IV injection	Contraindicated[1]
IV infusion	See PREPARATION. Infuse over 30 minutes.[1] Use a 0.2 micrometre inline filter if available. A filter is recommended but not required.[3]
COMPATIBILITY	
Fluids	Glucose 5%[1], sodium chloride 0.9%[1]
Y-site	Do not mix with other medicines
INCOMPATIBILITY	No information
SPECIAL NOTES	Monitor for possible anaphylactic and infusion reactions during the infusion and for one hour after the infusion.[1] Infusion reactions include fever, chills, dizziness, dyspnoea, pruritis and rash.[4] For mild to moderate infusion reactions, slow or stop the infusion and treat accordingly.[1] Anaphylactic reactions are rare but are a medical emergency. Stop the infusion and commence treatment immediately.[1,3]

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 26/08/2021.
2. Medical information. Withdrawal from infusion bag during dilution of sotrovimab [email]. Abbotsford, Vic: GSK; 19/10/2021.
3. Medical information. Use of a filter for administration of sotrovimab [email]. Abbotsford, Vic: GSK; 19/10/2021.
4. Xevudy. Australian public assessment report. August 2021. Available from www.tga.gov.au. Accessed 26/08/2021.